Synapse - Genitourinary Oncology Service

Results (304)

Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial

Journal Article

Powles, T. B.; Van der Heijden, M. S.; Loriot, Y.; Bedke, J.; Valderrama, B. P.; Iyer, G.; Kikuchi, E.; Hoffman-Censits, J.; Vulsteke, C.; Drakaki, A.; more...
Annals of Oncology (2025)

Fulltext@MSK | Save

ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice

Guidelines

Westphalen, C. B.; Boscolo Bielo, L.; Aftimos, P.; Beltran, H.; Benary, M.; Chakravarty, D.; Collienne, M.; Dienstmann, R.; El Helali, A.; Gainor, J.; more...
Annals of Oncology (2025)

Fulltext@MSK | Save

Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ-cell tumors

Journal Article

Matulewicz, R. S.; Baky, F.; Liso, N.; Williams, B. M.; Porwal, S.; Assel, M.; Carver, B. S.; Bajorin, D. F.; Motzer, R. J.; Bosl, G. J.; more...
Annals of Oncology (2025)

Fulltext@MSK | Save

Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: Final analysis of the phase III JAVELIN Renal 101 trial

Journal Article

Choueiri, T. K.; Penkov, K.; Uemura, H.; Campbell, M. T.; Pal, S.; Kollmannsberger, C.; Lee, J. L.; Venugopal, B.; van den Eertwegh, A. J. M.; Negrier, S.; more...
Annals of Oncology (2025)

Fulltext@MSK | Save

Biomarker analyses from the phase III randomized CLEAR trial: Lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma

Journal Article

Motzer, R. J.; Porta, C.; Eto, M.; Hutson, T. E.; Rha, S. Y.; Merchan, J. R.; Winquist, E.; Gurney, H.; Grünwald, V.; George, S.; more...
Annals of Oncology (2025)

Fulltext@MSK | Save

Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer

Journal Article

Rathkopf, D. E.; Patel, M. R.; Choudhury, A. D.; Rasco, D.; Lakhani, N.; Hawley, J. E.; Srinivas, S.; Aparicio, A.; Narayan, V.; Runcie, K. D.; more...
Annals of Oncology (2025)

Fulltext@MSK | Save

Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression

Meeting Abstract

Sternschuss, M.; Whiting, K.; Teo, M. Y.; Bajorin, D.; Kotecha, R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Alliance A031501: AMBASSADOR study of adjuvant pembrolizumab (Pembro) in muscle-invasive urothelial carcinoma (MIUC) vs observation (Obs): Extended follow-up disease-free survival (DFS) results and metastatic (met) disease recurrence distribution

Meeting Abstract

Apolo, A. B.; Ballman, K.; Sonpavde, G. P.; Berg, S.; Kim, W.; Parikh, R.; Teo, M. Y.; Sweis, R. F.; Geynisman, D.; Grivas, P.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)

Meeting Abstract

Powles, T. B.; van der Heijden, M. S.; Gupta, S.; Perez Valderrama, B.; Galsky, M. D.; Bedke, J.; Kikuchi, E.; Hoffman-Censits, J.; Maroto Rey, J. P.; Vulsteke, C.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2- expressing, locally advanced or metastatic urothelial carcinoma (la/mUC): RC48G001 cohort C

Meeting Abstract

Galsky, M. D.; Koshkin, V. S.; Campbell, M. T.; Drakaki, A.; Bowman, I.; Rose, A. A. N.; Brown, J. R.; Aragon-Ching, J. B.; Gadde, S.; Harandi, A.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save